HK1045655A1 - 由二甲雙胍及伏降糖組合構成的藥劑成份 - Google Patents

由二甲雙胍及伏降糖組合構成的藥劑成份

Info

Publication number
HK1045655A1
HK1045655A1 HK02107208.1A HK02107208A HK1045655A1 HK 1045655 A1 HK1045655 A1 HK 1045655A1 HK 02107208 A HK02107208 A HK 02107208A HK 1045655 A1 HK1045655 A1 HK 1045655A1
Authority
HK
Hong Kong
Prior art keywords
glibenclamide
metformin
combination
pharmaceutical composition
pharmaceutical
Prior art date
Application number
HK02107208.1A
Other languages
English (en)
Inventor
Anne Piper Beth
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23716278&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1045655(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2000/028311 external-priority patent/WO2001032157A2/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of HK1045655A1 publication Critical patent/HK1045655A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
HK02107208.1A 1999-11-03 2002-09-30 由二甲雙胍及伏降糖組合構成的藥劑成份 HK1045655A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/432,465 US6586438B2 (en) 1999-11-03 1999-11-03 Antidiabetic formulation and method
US09/460,920 US7598262B2 (en) 1999-11-03 1999-12-14 Method for treating diabetes
PCT/US2000/028311 WO2001032157A2 (en) 1999-11-03 2000-10-13 Pharmaceutical composition comprising a combination of metformin and glibenclamide

Publications (1)

Publication Number Publication Date
HK1045655A1 true HK1045655A1 (zh) 2002-12-06

Family

ID=23716278

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02107208.1A HK1045655A1 (zh) 1999-11-03 2002-09-30 由二甲雙胍及伏降糖組合構成的藥劑成份

Country Status (34)

Country Link
US (2) US6586438B2 (zh)
EP (1) EP1253944A2 (zh)
JP (2) JP2003529551A (zh)
KR (2) KR100769786B1 (zh)
CN (3) CN102283853A (zh)
AR (1) AR026355A1 (zh)
AU (1) AU781781B2 (zh)
BG (2) BG65850B1 (zh)
BR (1) BR0015295A (zh)
CA (1) CA2389931A1 (zh)
CZ (2) CZ304090B6 (zh)
DE (1) DE60038455T2 (zh)
EE (1) EE05210B1 (zh)
ES (1) ES2302702T3 (zh)
GE (2) GEP20053538B (zh)
HK (1) HK1045655A1 (zh)
HU (1) HUP0300642A3 (zh)
IL (3) IL149138A0 (zh)
LT (1) LT5025B (zh)
LV (1) LV12907B (zh)
MX (1) MXPA02004290A (zh)
MY (2) MY136636A (zh)
NO (1) NO20022086L (zh)
NZ (1) NZ552074A (zh)
PL (1) PL366112A1 (zh)
RO (1) RO123109B1 (zh)
RU (1) RU2276604C2 (zh)
SK (1) SK4992002A3 (zh)
TN (2) TNSN00207A1 (zh)
TW (1) TWI241185B (zh)
UA (2) UA75583C2 (zh)
UY (1) UY26425A1 (zh)
WO (1) WO2001032158A2 (zh)
ZA (2) ZA200203368B (zh)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235627B2 (en) * 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US6414002B1 (en) * 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US20030040469A1 (en) * 2000-03-08 2003-02-27 Knudsen Liselotte Bjerre Lowering serum lipids
MXPA02009130A (es) * 2000-03-17 2003-03-12 Ajinomoto Kk Farmacos para complicaciones de diabetes y neuropatia y utilizacion de los mismos.
FR2816840B1 (fr) 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
US7062312B2 (en) * 2001-01-17 2006-06-13 Pediamed Pharmaceuticals, Inc. Combination and method including a visual marker for determining compliance with a medication regimen
US20030022816A1 (en) * 2001-03-07 2003-01-30 Knudsen Liselotte Bjerre Combined use of derivatives of GLP-1 analogs and PPAR ligands
US20020187926A1 (en) * 2001-03-07 2002-12-12 Knudsen Liselotte Bjerre Combined use of derivatives of GLP-1 analogs and PPAR ligands
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
HUP0402328A2 (hu) * 2001-09-28 2005-02-28 Sun Pharmaceutical Industries Limited Diabétesz mellitusz kezelésére szolgáló gyógyszerkészítmény
US6924311B2 (en) * 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
US7183321B2 (en) * 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
EP1482919B1 (en) * 2002-01-25 2007-05-02 Laboratorios Silanes, S.A. de C.V. Pharmaceutical composition that is used to control blood glucose in patients with type 2 diabetes
US7906145B2 (en) 2002-04-09 2011-03-15 Flamel Technologies Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
WO2003105809A1 (en) 2002-06-17 2003-12-24 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
ATE432289T1 (de) * 2002-07-04 2009-06-15 Zealand Pharma As Glp-1 und behandlungsmethode für diabetes
JP2004067575A (ja) * 2002-08-06 2004-03-04 Yaizu Suisankagaku Industry Co Ltd 糖尿病治療薬効果促進剤
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
SE526943C2 (sv) * 2002-08-26 2005-11-22 Indevex Ab Födoämneskompositionsprodukt
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
US20040147564A1 (en) * 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
DE60331236D1 (de) * 2003-07-24 2010-03-25 Eswaran Krishnan Iyer Orale zusammensetzungen zur behandlung von diabetes
ATE433994T1 (de) * 2003-07-25 2009-07-15 Conjuchem Biotechnologies Inc Insulinderivative mit langanhaltender wirkung und verfahren zu deren herstellung
US20050202063A1 (en) * 2003-08-26 2005-09-15 Ebn International Kft Food product
WO2005065654A2 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Rosiglitazone formulations
US20050163842A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone and metformin formulations
WO2005107750A1 (en) * 2004-04-29 2005-11-17 Andrx Labs. Llc Controlled release metformin compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20060188590A1 (en) * 2005-01-05 2006-08-24 Mitsunori Ono Compositions for treating diabetes or obesity
EP1891971A4 (en) * 2005-01-31 2010-02-03 Ajinomoto Kk MEDICAL COMPOSITION USING HYPERGLY CRAB MEDICAMENT TO TREAT OR TREAT GLUCOSE-INTOLERANCE, BORDERLINE DIABETES, INSULIN RESISTANCE AND HYPERINSULINEMIA
EP1889618A4 (en) * 2005-05-27 2010-11-24 Daiichi Sankyo Co Ltd COMBINED MEDICINE FOR THE TREATMENT OF DIABETES
CA2632607A1 (en) * 2005-12-09 2007-06-21 Metaproteomics, Llc Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
US20090042863A1 (en) * 2005-12-28 2009-02-12 Takeda Pharmaceutical Company Limited Therapeutic Agent for Diabetes
FR2896157B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
JP5323684B2 (ja) 2006-05-04 2013-10-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 多形体
JP2009544630A (ja) * 2006-07-26 2009-12-17 デイアメデイカ・インコーポレイテツド 代謝障害の診断及び治療方法
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
US20100136561A1 (en) * 2008-05-16 2010-06-03 Interleukin Genetics, Inc. Genetic Markers for Weight Management and Methods of Use Thereof
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101189639B1 (ko) * 2008-12-15 2012-10-12 씨제이제일제당 (주) 메트포르민 및 α-글리코시다제 억제제를 포함하는 경구 제제 및 그 제조방법
DK3222277T3 (da) 2009-03-31 2020-05-11 Ligand Pharm Inc Biphenylsulfonamidendothelin- og angiotensin II-receptorantagonist til behandling af glomerulosklerose og IgA-induceret nefropati
LT3278665T (lt) 2009-04-29 2020-12-10 Amarin Pharmaceuticals Ireland Limited Stabili farmacinė kompozicija ir jos panaudojimo būdai
EP3791880A1 (en) 2009-04-29 2021-03-17 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa
ES2856959T3 (es) 2009-06-15 2021-09-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para el tratamiento del ictus en un sujeto en terapia simultánea con estatina
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
EP2504002B1 (en) 2009-11-27 2019-10-09 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
CN101810628B (zh) * 2010-04-13 2012-05-23 北京四环科宝制药有限公司 二甲双胍格列吡嗪片及其制备方法
JP5969461B2 (ja) 2010-04-27 2016-08-17 ジーランド ファーマ アクティーゼルスカブ Ｇｌｐ−１受容体作動薬とガストリンとのペプチド複合体及びその使用
MX341025B (es) 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
MY187718A (en) 2010-05-11 2021-10-14 Janssen Pharmaceutica Nv Pharmaceutical formulations
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US20140127289A1 (en) 2010-11-29 2014-05-08 Armarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2012090225A2 (en) * 2010-12-29 2012-07-05 Nutracryst Therapeutics Private Limited Novel cocrystals / molecular salts of metformin with oleoylethanolamide as an effective anti-diabetic + anti- obesity agent
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
EA039943B1 (ru) 2011-01-07 2022-03-30 Анджи Фарма (Юс) Элэлси Способ снижения уровней глюкозы в крови у субъекта
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
MX2014005351A (es) 2011-11-03 2014-05-28 Zealand Pharma As Conjugados de gastrina peptidicos de agonistas de receptor glp-1.
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2800562A2 (en) 2012-01-06 2014-11-12 Elcelyx Therapeutics, Inc. Compositions and methods for treating metabolic disorders
JP2015503582A (ja) 2012-01-06 2015-02-02 エルセリクス セラピューティクス インコーポレイテッド ビグアナイド組成物および代謝障害を治療する方法
WO2013115742A1 (en) * 2012-01-31 2013-08-08 Mahmut Bilgic Pharmaceutical composition comprising alpha-glucosidase inhibitor
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
PL2854841T3 (pl) 2012-06-04 2017-08-31 Diamedica Inc. Izoformy glikozylacji ludzkiej kalikreiny tkankowej 1
CA2878991C (en) 2012-07-23 2021-12-07 Zealand Pharma A/S Glucagon analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
KR101336499B1 (ko) * 2013-03-06 2013-12-03 씨제이제일제당 (주) 당뇨병의 예방 또는 치료용 복합 조성물
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
AR098065A1 (es) 2013-10-17 2016-04-27 Zealand Pharma As Análogos de glucagón acilados
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
WO2015067715A2 (en) 2013-11-06 2015-05-14 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
EA035688B1 (ru) 2013-11-06 2020-07-27 Зилэнд Фарма А/С Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
EP3985016A1 (en) 2014-10-29 2022-04-20 Zealand Pharma A/S Gip agonist compounds and methods
KR20170137198A (ko) 2015-04-16 2017-12-12 질랜드 파마 에이/에스 아실화된 글루카곤 유사체
EP4233840A3 (en) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
SG11201903938XA (en) 2016-12-09 2019-05-30 Zealand Pharma As Acylated glp-1/glp-2 dual agonists
KR20190122706A (ko) 2017-03-09 2019-10-30 다이어메디카 인코포레이티드 조직 칼리크레인 1의 투약 형태
PT4056176T (pt) 2018-09-24 2024-05-27 Amarin Pharmaceuticals Ie Ltd Métodos de redução do risco de eventos cardiovasculares num indivíduo
CN113648318B (zh) * 2020-05-12 2023-08-25 中国科学院上海营养与健康研究所 增强细胞产热和治疗疾病的应用
KR20240012390A (ko) 2021-04-21 2024-01-29 애머린 파마슈티칼스 아일랜드 리미티드 심부전의 위험을 감소시키는 방법

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
US4060634A (en) 1973-09-26 1977-11-29 Boehringer Mannheim G.M.B.H. Rapidly resorbable glibenclamide
DE2348334C2 (de) 1973-09-26 1982-11-11 Boehringer Mannheim Gmbh, 6800 Mannheim Neue Zubereitungsform des N-4-[2-(5-Chlor-2-methoxybenzamido)äthyl]- phenyl-sulfonyl-N'-cyclohexylharnstoffs
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
EP0062704A1 (de) 1980-12-03 1982-10-20 Hoechst Aktiengesellschaft Cyclopropancarbonsäureester-derivate als Mittel zum Bekämpfen von Magendasseln bei Equiden
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4916163A (en) 1985-06-04 1990-04-10 The Upjohn Company Spray-dried lactose formulation of micronized glyburide
DE3543999A1 (de) 1985-12-13 1987-06-19 Bayer Ag Hochreine acarbose
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
DE3833439A1 (de) 1988-10-01 1991-09-12 Hoechst Ag Verfahren zur mikronisierung von glibenclamid
US5258185A (en) * 1989-08-23 1993-11-02 Bauer Kurt H Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
DE4323636A1 (de) 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it) 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US6153632A (en) 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
PT998271E (pt) * 1997-06-06 2005-10-31 Depomed Inc Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis
WO1998056378A1 (en) 1997-06-13 1998-12-17 Novo Nordisk A/S Novel niddm regimen
KR20060105005A (ko) 1997-06-18 2006-10-09 스미스클라인비이참피이엘시이 티아졸리딘디온 및 메트포르민을 사용한 당뇨병의 치료
GB9715306D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
CN1302206A (zh) 1997-10-17 2001-07-04 阿温蒂斯药物制品公司 喹啉衍生物的治疗用途
ES2216335T3 (es) 1997-12-08 2004-10-16 Bristol-Myers Squibb Company Nuevas sales de metformina y procedimiento.
FR2774591B1 (fr) 1998-02-12 2000-05-05 Lipha Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
FI111167B (fi) * 1998-02-24 2003-06-13 Kemira Chemicals Oy Menetelmä lietteen säilyvyyden parantamiseksi
JP2002508162A (ja) 1998-02-27 2002-03-19 ノボ ノルディスク アクティーゼルスカブ Ｎ末端を短縮したｇｌｐ−１誘導体
ATE250418T1 (de) 1998-07-15 2003-10-15 Merck Sante Sas Tabletten enthaltend eine kombination von glibenclamid und metformin
EP1113801A4 (en) 1998-09-17 2002-10-02 Bristol Myers Squibb Co METHOD FOR TREATING ATHEROSCLEROSIS WITH AN AP2 INHIBITOR OR COMBINATION
AR028299A1 (es) 1999-09-17 2003-05-07 Novartis Ag Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
EP2620443A1 (en) 2012-01-25 2013-07-31 Galecto Biotech AB Novel galactoside inhibitors of galectins

Also Published As

Publication number Publication date
CN100386114C (zh) 2008-05-07
EP1253944A2 (en) 2002-11-06
GEP20053538B (en) 2005-06-10
LT5025B (lt) 2003-06-25
LT2002062A (en) 2003-03-25
NO20022086L (no) 2002-06-24
ES2302702T3 (es) 2008-08-01
CN1414862A (zh) 2003-04-30
EE05210B1 (et) 2009-10-15
AU781781B2 (en) 2005-06-16
LV12907B (en) 2003-08-20
DE60038455D1 (de) 2008-05-08
CZ20021547A3 (cs) 2003-01-15
RU2276604C2 (ru) 2006-05-20
DE60038455T2 (de) 2009-04-23
MXPA02004290A (es) 2003-02-12
WO2001032158A3 (en) 2002-08-29
US7598262B2 (en) 2009-10-06
IL149138A (en) 2007-12-03
UY26425A1 (es) 2001-07-31
NZ552074A (en) 2008-06-30
BR0015295A (pt) 2003-06-24
KR20020057994A (ko) 2002-07-12
MY136636A (en) 2008-11-28
BG106732A (bg) 2003-02-28
TNSN00206A1 (en) 2005-11-10
PL366112A1 (en) 2005-01-24
SK4992002A3 (en) 2003-04-01
TNSN00207A1 (en) 2005-11-10
CA2389931A1 (en) 2001-05-10
JP2013028631A (ja) 2013-02-07
HUP0300642A3 (en) 2006-05-29
WO2001032158A2 (en) 2001-05-10
NO20022086D0 (no) 2002-05-02
KR100769786B1 (ko) 2007-10-24
GEP20053539B (en) 2005-06-10
CZ304090B6 (cs) 2013-10-16
BG65850B1 (bg) 2010-03-31
RO123109B1 (ro) 2010-11-30
US20020183345A1 (en) 2002-12-05
IL149138A0 (en) 2002-11-10
UA76706C2 (uk) 2006-09-15
US6586438B2 (en) 2003-07-01
RU2002113764A (ru) 2004-03-20
US20020177602A1 (en) 2002-11-28
KR20020050253A (ko) 2002-06-26
AU8022900A (en) 2001-05-14
CN102283853A (zh) 2011-12-21
AR026355A1 (es) 2003-02-05
UA75583C2 (uk) 2006-05-15
JP2003529551A (ja) 2003-10-07
TWI241185B (en) 2005-10-11
EE200200241A (et) 2003-12-15
MY125118A (en) 2006-07-31
CN101273981A (zh) 2008-10-01
CN101273981B (zh) 2011-01-26
ZA200203367B (en) 2003-09-10
ZA200203368B (en) 2003-09-02
BG106733A (bg) 2003-02-28
HUP0300642A2 (hu) 2003-07-28
IL149139A (en) 2011-11-30

Similar Documents

Publication Publication Date Title
HK1045655A1 (zh) 由二甲雙胍及伏降糖組合構成的藥劑成份
PL364885A1 (en) Pharmaceutical composition comprising a combination of metformin and glibenclamide
SI0974356T1 (en) Tablets comprising a combination of metformin and glibenclamide
HUP0002209A3 (en) 4-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives and pharmaceutical compositions containing them
HUP0104497A3 (en) Benzamide derivatives, their preparation, medicaments containing them and their use
IL148168A0 (en) Pharmaceutical composition of nateglinide and another antidiabetic agent
HUS1400025I1 (hu) Feniletanolamin-származékok és az ezeket tartalmazó gyógyszerek
PT1213020E (pt) Compostos e composições farmacêuticas com actividade supressora do apetite
PL337348A1 (en) Pharmaceutic composition comprising a combination of piperidinylalkanol and a decongestant
HUP0203939A3 (en) Pharmaceutical compounds and compositions containing them and their use
HUP0100801A3 (en) Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intented to reduce hyperglycaemia
IL155196A0 (en) Benzamide derivatives and pharmaceutical compositions containing the same
HK1065798A1 (en) Pharmaceutical compositions comprising tachykininsantagonists and a serotonin reuptake inhibitor
ZA985136B (en) Pharmaceutical aerosol composition
HUP0001309A3 (en) 1-phenyl-4-benzylpiperazines and pharmaceutical compositions containing them
IL150383A0 (en) Glyburide and pharmaceutical compositions containing the same
HUP0105204A3 (en) Substituted phenethylamine derivatives and pharmaceutical compositions containing them
IL139775A0 (en) A substituted triazolo-pyridazine derivative and pharmaceutical compositions made therefrom
HUP0201433A2 (en) Mutual prodrugs of amlodipine and atorvastatin, pharmaceutical compositions containing them and the use of prodrugs
HUP0200747A2 (en) Pharmaceutical compounds and pharmaceutical compositions containing them
HUP0201910A3 (en) Novel aminobenzophenones, pharmaceutical compositions containing them and their use
HUP0101701A3 (en) Substituted betha-alanines and pharmaceutical compositions comprising them
HUP0002331A3 (en) 20-aralkyl-5alpha-pregnane derivatives and pharmaceutical compositions thereof
HUP0001940A3 (en) Benzisothiazole derivatives, their use and pharmaceutical compositions containing them
HUP0003189A3 (en) Pharmaceutical composition comprising fexofenadine and its derivatives